I Our Main Service

- **XImporting / Technology Transfer for Finish Dosage Form**

Ⅱ Our Hot Items

- i "Me-too" new drugs development; API advanced intermediates(Avoid current patent) ----Key intermediates for Sartan series, tatin series, Liptin series, Dipine Series, Tinib series etc.
- ii Polypeptide derivatives---Glatiramer, Liraglutide for R&D etc.
- iii Prostaglandin Derivatives---Cloprostenol Key intermediates etc.
- iv **Multi-step synthesis** skills including chiral compound(more than 15 steps) and Scale-up in KG and Process Optimization.
- v **PEG Chemistry**: PEGylation drugs(**4-Arm-PEG-Gyl-Irinotecan** and **PEG-Naloxone**),PEG conjugates and proteins for long term controlled released drugs.
- vi **Drug delivery system:** Block copolymers and "proof-of-concept" for uses in DDS;(For example: Lipids)



Custom Developing/Custom Manufacturing



possibility 1 week - 2 weeks

PILOT SCALE

 evaluate the cost and quality

3 months

LAB SCALE

evaluate the quality
 make sample

1 month

COMMERCIAL PRODUCTION

6 months

We can do...

We are professional of these compounds

- 1. Chiral compounds
- 2. Carbohydrate chemistry
- Peptide synthesis
- 4. Create a new synthetic route which is different from patent route(avoid patant)



- 1. Grignard reagent
- 2. Oxidation / Reduction
- 3. Ring closure reaction
- 4. Condensation reaction
- Halogenation
- 6. Nitration
- 7. Amination



We have special facilities that can meet these circumstances

- 1. High vacuum (reach 1mmHg)
- 2. Low temperature (reach -100°C)
- 3. Enzymic catalytic reaction

Tel: 0086-592-5853819 xie@china-sinoway.com pan@china-sinoway.com



Importing/Technology Transfer for Finish Dosage Form

Prescription drug preparations in Neurology and Psychiatry

Importing /Technology Transfer for FDF

- 1. Pain Management
- 2. Gastric Ulcer
- 3. Cardiovascular System
- 4. Nutriology
- 5. Neurology, Psychiatry: Alzheimer, Parkinson etc.

New technology in Drug Delivery System

Step 1

- 1. Information exchange after signing CDA
- · 2. Letter of Intention
- · 3. Cooperation agreement

Step 2

· Import Registration in China (3-5 years)

Step 3

Import by large package and sub-package in China

Step 4

Technology transfer or keep importing



Pharmaceutical Peptides

Product Name	CAS No.	Specification
Liraglutide Acetate	204656-20-2	99% up by HPLC, S. Impurity<0.1% for R&D
Teriparatide Acetate	52232-67-4	98% up by HPLC
Glatiramer Acetate	147245-92-9	98% up for HPLC
Gonadorelin Acetate	34973-08-5	98% up by HPLC
Octreotide Acetate	83150-76-9	USP/EP
Oxytocin Acetate	50-56-6	98% up by HPLC
Eptifibatide Acetate	148031-34-9	USP/EP

Prostaglandin Derivatives

Product Name	CAS No.	Specification
Prostaglandin series	32233-40-2;	99% up by HPLC
key Intermediates	70764-05-7;	
Travoprost	54142-64-2;	99% up by HPLC
Intermediates	208111-98-2 etc.	
Bimatoprost	41162-19-0;	99% up by HPLC
Intermediates	41639-74-1 etc.	
Latanoprost	352276-28-9	99% up by HPLC
Intermediates	41639-83-2 etc	
Cloprostenol	54324-79-7	99% up by HPLC
Intermediates	54713-44-9 etc	



Pharmaceutical Intermediates

Product Name	CAS No.	Specification
Rosuvastatin calcium	147118-40-9;	99% up by HPLC
intermediates	147118-35-2 etc.	S. Impurity<0.1%
Pitavastatin calcium	147511-70-4;	99.5%up by HPLC
intermediates	147489-06-3 etc.	S. Impurity<0.1%
Sorafenib Intermediates	284462-37-9 etc.	99%up by HPLC
Febuxostat intermediates	160844-75-7 etc.	99%up by HPLC
Entecavir intermediate	1354715-15-3etc	99% up by HPLC
Solifenacin succinate	118864-75-8 etc.	99%up by HPLC
intermediates		
Rivaroxaban_	446292-07-5 etc.	99%up by HPLC
intermediates	440232-07-3 610.	
1.3-Dichloro Acetone	534-07-6	99%up by HPLC
P-Hydroxybenzyl alcohol	623-05-2	99%up by HPLC



APIs

Product Name	Quality	Developing Status
Nifuratel	99.9%up by HPLC	GMP ,DMF preparation
Cinacalcet Hcl	99.9%up by HPLC	GMP ,DMF
Azilsartan(Medoxomil)	99%up by HPLC	DMF,PMDA
Esomeprazole	99%up by HPLC	GMP application,
Magnesium dihydrate		DMF; PMDA
Rabeprazole sodium	CP, JP	GMP, DMF ,PMDA
Choline glycerophos	99%up by HPLC	GMP application
phate (GPC)		DMF preparation
Pregabalin	99%up by HPLC	GMP,DMF,PMDA
Ezetimibe	99%up by HPLC	GMP,DMF,PMDA
Dabigatran Etexilate	99%up by HPLC	GMP application,
Mesylate		DMF,PMDA
Palonosetron HCL	99%up by HPLC	GMP, DMF,PMDA
Vildagliptin	99%up by HPLC	R&D
Linagliptin	99%up by HPLC	R&D



APIs

Product Name	Quality	Developing Status
Ibandronate Sodium	98.5%~101.5%	GMP, DMF
hydrate	Single impurity≤0.10%	
Dasatinib hydrate	99%up by HPLC	,DMF,PMDA, GMP application
	Single impurity≤0.10%	
Erlotinib	99%up by HPLC	,DMF, PMDA, GMP application
hydrochloride	Single impurity≤0.10%	
Bortezomib	99%up by HPLC	PMDA, DMF preparation,
	Single impurity≤0.10%	
Capecitabine	USP/EP	FDA,CEP,DMF
Lenalidomide	98.0%~102.0%	DMF, PMDA
	Single impurity≤0.10%	FDA application,
Canagliflozin	Amorphous form 98.0%~102.0%	Under PV, DMF,PMDA
hemihydrate	Single impurity≤0.10%	
LCZ696	Assay of Valsartan49.8%~52.4%	Pilot scale, PMDA
	Assay of Sacubitril 49.8%~52.4%	DMF preparation,
	Single impurity≤0.10%	
Ticagrelor	99%up by HPLC	DMF,PMDA, FDA application
	Single impurity≤0.10%	, ,
Sofosbuvir	Forml, Formll, Amorphous 98.0%~102.0%	DMF, PMDA
	Single impurity≤0.10%	